Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nawar Najjar

Internal Medicine Raynham, MA Medical Doctor

NPI 1265445068 CMS profile 940906

675 Paramount Dr Ste 203, Raynham, MA 02767

Open in the dashboard

General payments

$9,472

513 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nawar Najjar of Raynham, MA is reported in the CMS Open Payments database as having received $9,472 across 513 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,461 58
2024 General $1,968 88
2023 General $1,351 69
2022 General $1,527 87
2021 General $1,534 103
2020 General $555 32
2019 General $1,075 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nawar Najjar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nawar Najjar were reported at $1,461. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nawar Najjar Internal Medicine median Middle half National median
2019 $1,075 $159 $48–$570 $163
2020 $555 $119 $33–$402 $114
2021 $1,534 $135 $37–$521 $132
2022 $1,527 $141 $42–$496 $149
2023 $1,351 $149 $45–$519 $160
2024 $1,968 $154 $47–$537 $164
2025 $1,461 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,566 66 payments
  2. Novo Nordisk Inc $947 50 payments
  3. Pfizer Inc. $883 69 payments
  4. AbbVie, Inc. $789 47 payments
  5. GlaxoSmithKline, LLC. $684 42 payments
  6. Janssen Pharmaceuticals, Inc $448 25 payments
  7. Novartis Pharmaceuticals Corporation $379 24 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $299 14 payments
  9. Nestle HealthCare Nutrition Inc. $277 18 payments
  10. Lilly USA, LLC $256 13 payments
  11. Other $2,943 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,472 513 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,047 46 payments
  2. TRELEGY ELLIPTA $508 30 payments
  3. Ozempic $468 25 payments
  4. XARELTO $448 25 payments
  5. SPIRIVA RESPIMAT $401 18 payments
  6. RYBELSUS $386 21 payments
  7. BREZTRI $366 9 payments
  8. VRAYLAR $325 16 payments
  9. AIRSUPRA $324 12 payments
  10. ELIQUIS $319 19 payments
  11. Other $8,025 486 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 173 drugs

Part D claims

11,830

Median for Internal Medicine: 777

Drug cost

$1,110,991

Median for Internal Medicine: $73,373

Branded share of claims

21.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 193 $165,600
Trulicity Dulaglutide Brand 129 $138,432
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 122 $112,904
Ozempic Semaglutide Brand 73 $104,005
Zenpep Lipase/Protease/Amylase Brand 23 $57,545
Jardiance Empagliflozin Brand 51 $47,064
Januvia Sitagliptin Phosphate Brand 47 $41,665
Xarelto Rivaroxaban Brand 38 $40,385
Tradjenta Linagliptin Brand 32 $33,838
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 66 $33,776

The 10 drugs with the highest cost, of 173 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$264,502

Of which drugs: $21,368

Medicare patients

814

Average age 75

Services billed

4,215

426 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 36%
Chronic kidney disease 31%
Depression 25%
Ischemic heart disease 22%
Atrial fibrillation 20%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 162 162 $13,169
Pcv20 vaccine im 90677 Office 22 22 $6,097
Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage 90694 Office 12 12 $910
Influenza vaccine, trivalent derived from cell cultures 90661 Office 15 15 $492
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 13 29 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $204
$204 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $169
$169 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $158
$158 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $126
$126 35 —
Wegovy
  • Novo Nordisk Inc $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record